Delve into the world of diabetes treatment innovation with leading diabetology expert and grab latest insights on Imeglimin, a dual-action novel agent for Type 2 Diabetes Mellitus (T2DM). In this session, you'll gain insights into the Imeglimin's mechanism of action at a cellular and molecular level, clinical efficacy, and potential advantages of Imeglimin in managing T2DM. Join us for a comprehensive overview of this promising therapeutic option that may shape the future of diabetes care.

Imeglimin - The Dual Action Novel Agent for T2DM

RCP Diabetology Day-4

Sr. Endocrinologist, Apollo Speciality Hospitals, Chennai, Specializes in type 1 & type 2 diabetes, endocrine disorders, thyroid disorders, and hormonal disorders.

Persistent hypertension despite treatment can often point towards underlying aldosterone-mediated mechanisms. This expert-led session will explore the role of aldosterone in difficult-to-control hypertension, approaches to identifying patients with aldosterone-driven disease, and evolving strategies for targeted management. The discussion will also examine the emerging role of Aldosterone Synthase Inhibitors (ASI) and their potential to address unmet needs in patients with persistently uncontrolled blood pressure. Featuring insights from Dr. Vijay Kher, Prof. Dr. David Wheeler, and Dr. A G Unnikrishnan, the session will focus on practical perspectives and the evolving evidence shaping the future of hypertension management.

Dr. Krishna Seshadri

3

754

43.4k

4.7

Upcoming Sessions

Sessions Taken

781

4.7

0

0